The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUniphar Regulatory News (UPR)

Share Price Information for Uniphar (UPR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 223.00
Bid: 220.00
Ask: 226.00
Change: 0.00 (0.00%)
Spread: 6.00 (2.727%)
Open: 223.00
High: 223.00
Low: 223.00
Prev. Close: 223.00
UPR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Joint Corporate Broker

9 Dec 2020 07:00

RNS Number : 9700H
Uniphar PLC
09 December 2020
 

Appointment of Joint Corporate Broker

 

 

 

Dublin, London | 9 December 2020: Uniphar plc ("Uniphar" or the "Group") today announces that it has appointed Stifel Nicolaus Europe Limited as its joint corporate broker, alongside Davy and RBC Capital Markets, with immediate effect.

 

--Ends--

 

For further details contact:

 

Uniphar

+353 (0) 1 428 7777

 

 

Brian O'Shaughnessy

 

Group Director of Corporate Development

investor.relations@Uniphar.ie

 

 

Davy

+353 (0) 1 679 6363

(Joint Corporate Broker, Nominated Adviser and Euronext

Growth Adviser)

 

 

 

Fergal Meegan

 

Barry Murphy

 

Orla Cowzer

 

 

 

RBC Capital Markets (Joint Corporate Broker)

+44 (0) 20 7653 4000

 

 

Darrell Uden

 

Jonathan Hardy

 

Jamil Miah

 

 

 

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

+44 (0) 20 7710 7600

Matt Blawat

 

Ben Madison

 

Francis North

 

 

 

Q4 PR

+353 (0) 1 475 1444 or

(Public Relations Adviser to Uniphar)

+353 87 235 6461

 

 

Iarla Mongey

 

 

 

 

About Uniphar plc 

 

Headquartered in Dublin, Ireland, Uniphar plc is an international diversified healthcare services business, servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail.

 

The Group has strong established relationships with 7 of the top 10 pharma companies and 6 of the top 10 medical device companies. With a workforce of more than 2,600, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US, delivering unlicensed and specialty medicine on a global basis.

 

The Group's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

 

Commercial & Clinical

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, the Benelux, and the Nordics, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by highly experienced, clinically trained teams to deliver exceptional outcomes for all clients.

 

Product Access

In Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

 

Supply Chain & Retail

Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.330 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPEASAPEFNEFFA
Date   Source Headline
3rd Dec 20217:00 amRNSHolding(s) in Company
23rd Nov 20213:22 pmRNSHolding(s) in Company
15th Nov 20214:02 pmRNSHolding(s) in Company
14th Oct 202111:31 amRNSHolding(s) in Company
7th Sep 20217:00 amRNSHolding(s) in Company
3rd Sep 20217:00 amRNSDirector/PDMR Shareholding
1st Sep 20217:00 amRNS2021 Interim Results
19th Aug 20215:24 pmRNSHolding(s) in Company
2nd Aug 20217:00 amRNSAcquisition of BESTMSLs Group
27th Jul 20217:00 amRNSHalf Year Trading Update and Notice of Results
20th Jul 20217:00 amRNSAcquisition of CoRRect Medical GmbH
12th May 20213:12 pmRNSResult of AGM
12th May 20217:00 amRNSAGM Statement
10th May 20218:29 amRNSHolding(s) in Company
7th May 20218:00 amRNSDirector/PDMR Shareholding
27th Apr 202112:44 pmRNSHolding(s) in Company
16th Apr 20214:59 pmRNSHolding(s) in Company
8th Apr 20217:00 amRNSNotice of AGM & Annual Report
4th Mar 20217:30 amRNSDirector/PDMR Shareholding
4th Mar 20217:30 amRNSExecutive Restricted Share Plan Dealing
2nd Mar 20217:00 amRNS2020 Preliminary Results
25th Feb 20217:00 amRNSConsent to Migration
15th Feb 20213:00 pmRNSResult of EGM
28th Jan 20213:57 pmRNSHolding(s) in Company
27th Jan 20217:00 amRNSDirectorate Changes
27th Jan 20217:00 amRNSFull Year Trading Update & Notice of Results
20th Jan 20219:00 amRNSCurrency Change on LSE
20th Jan 20217:00 amRNSNotice of EGM
7th Jan 20214:27 pmRNSHolding(s) in Company
22nd Dec 20203:00 pmRNSDirector/PDMR Shareholding
9th Dec 20207:00 amRNSAppointment of Joint Corporate Broker
24th Nov 20207:00 amRNSAcquisition of RRD International
23rd Nov 20207:00 amRNSAcquisition
2nd Nov 20203:30 pmRNSHolding(s) in Company
23rd Sep 20207:00 amRNSAcquisition of Diligent Health Solutions
21st Sep 20202:37 pmRNSDirector/PDMR Shareholding
18th Sep 20201:12 pmRNSHolding(s) in Company
18th Sep 202012:00 pmRNSDirectorate Change
11th Sep 20205:02 pmRNSDirector/PDMR Shareholding
11th Sep 20205:01 pmRNSDirector/PDMR Shareholding
2nd Sep 20207:00 amRNS2020 Interim Results
26th Aug 20204:41 pmRNSSecond Price Monitoring Extn
26th Aug 20204:36 pmRNSPrice Monitoring Extension
28th Jul 20207:00 amRNSHalf Year Trading Update and Notice of Results
23rd Jul 20206:32 pmRNSHolding(s) in Company
23rd Jul 20202:11 pmRNSHolding(s) in Company
30th Jun 20207:00 amRNSDirectorate Change
2nd Jun 20203:23 pmRNSHolding(s) in Company
26th May 20202:16 pmRNSResult of AGM
26th May 20207:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.